Complement activation in IgA nephropathy
File(s)
Author(s)
Medjeral-Thomas, Nicholas R
Cook, H Terence
Pickering, Matthew C
Type
Journal Article
Abstract
IgA nephropathy pathogenesis is incompletely understood, and this limits the development of disease-specific biomarkers and effective therapies. Evidence of complement activity in IgA nephropathy is well established. However, a growing body of research indicates complement activity is an important contributor to IgA nephropathy pathology. In particular, multiple associations have been identified between complement alternative, lectin and terminal pathway proteins and IgA nephropathy severity. Recently, we have also gained insight into possible mechanisms that could link glomerular IgA deposition, complement activity, glomerular inflammation and disease severity. Ongoing clinical trials of therapeutic complement inhibitors will provide insight into the importance of complement activity to IgA nephropathy pathogenesis. Further research into mechanisms of complement activity is essential to improving our understanding and management of patients with IgA nephropathy.
Date Issued
2021-08-11
Date Acceptance
2021-07-23
Citation
Springer Seminars in Immunopathology, 2021, 43, pp.679-690
ISSN
1863-2297
Publisher
Springer Verlag
Start Page
679
End Page
690
Journal / Book Title
Springer Seminars in Immunopathology
Volume
43
Copyright Statement
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Sponsor
Wellcome Trust
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000684083000002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
212252/Z/18/Z
Subjects
Science & Technology
Life Sciences & Biomedicine
Immunology
Pathology
Complement
IgA nephropathy
MANNAN-BINDING LECTIN
H-RELATED PROTEIN-5
GLOMERULAR DEPOSITION
PATHWAY
ECULIZUMAB
C3
SUSCEPTIBILITY
PATHOGENESIS
VARIANTS
INSIGHTS
Publication Status
Published
Date Publish Online
2021-08-11